Nucleophosmin mutations lead to abnormal, but reversible, nucleoli architecture and aggregate formation - Implications for NPM1-targeting therapies in AML (2024)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2024.12.30.630786
Publication URI: http://dx.doi.org/10.1101/2024.12.30.630786
Type: Preprint